Cytochrome P450 enzyme CYP3A4 is an important drug metabolizing enzyme and high levels of tumoral expression of CYP3A4 are linked to drug resistance. We investigated the function of vitamin D-regulated miR-627 in intratumoral CYP3A4 suppression and its role in enhancing the efficacy of chemotherapy. We found that miR-627 targets CYP3A4 and suppresses CYP3A4 expression in colon cancer cell lines. Furthermore, calcitriol (the active form of vitamin D) suppressed CYP3A4 expression by activating miR-627.
Introduction
Drug resistance is a major problem that prevents chemotherapy from achieving satisfying responses in patients. Traditionally, studies on drug resistance have focused on mechanisms including multidrug resistance mediated by multidrug resistanceassociated protein 1 (MRP1) (1) and P-glycoprotein (2), resistance to apoptosis mediated by anti-apoptotic proteins (3), amplification of drug target genes (4), etc.
However, a potentially significant drug resistance mechanism, cytochrome P450-mediated intratumoral drug metabolism, has received minimal attention.
Cytochrome P450 3A4 (CYP3A4) is one of the most abundant P450 enzymes expressed in human liver and the gastrointestinal tract. CYP3A4 contributes to the metabolism of approximately 50% the drugs currently used in the clinic (5) . In cancer chemotherapy, CYP3A4 has been associated with drug inactivation and high levels of tumoral expression of CYP3A4 are linked to drug resistance and poor response to therapy (6) (7) (8) (9) (10) . Irinotecan, a camptothecin derivative, is one of the major drugs used for the treatment of colorectal cancers (11) (12) , with APC as the major inactive metabolite. induces CYP3A4 overexpression in colon cancer by activating the steroid and xenobiotic receptor (SXR), subsequently leading to resistance to irinotecan (13) .
Furthermore, CYP3A4 expression is increased in colon cancer cells that exhibit cancer stem cell-like characters (14) , potentially contributing to multidrug resistance.
Importantly, CYP3A4 is expressed at substantially higher levels in the normal colon and colon cancers than those in the liver (15) , indicating that the intratumoral CYP3A4 may play a critical role in drug metabolism and resistance to chemotherapy in colon cancer.
Preclinical research has demonstrated clear antitumor activities of vitamin D against various types of cancers, including colon cancer (16) . Vitamin D analogs have been shown to enhance the antitumor activity of irinotecan in a colon cancer nude mouse xenograft model (17) , even though the underlying mechanism is not clear. We recently identified miR-627 as the sole miRNA whose expression was significantly increased by calcitriol (1α,25(OH) 2 D 3 , the active form of vitamin D) in colon cancer cells (18) . MiRNAs are small single-stranded non-coding RNAs that silence target genes by cleaving mRNA molecules or inhibiting translation (19) . Studies have shown that miRNAs can regulate cancer pathogenesis, cell cycle progression (20, 21) , differentiation (22, 23) , metabolism (24, 25) , invasion and metastasis (26, 27) , as well as apoptosis (28, 29) . We further demonstrated that miR-627 targets CYP3A4 and suppresses CYP3A4 expression. Because CYP3A4 is responsible for the inactivation of irinotecan, we here report that by activating miR-627 to suppress CYP3A4, vitamin D can enhance the therapeutic efficacy of irinotecan to achieve better cancer suppression. CAGTTCTTTGTT ACAAAATGTACGTG). The 3'UTR cDNA was inserted into pEGFP-C1 plasmid at the 3' end of the EGFP cDNA (Xho I and BamH I). The pEGFP-C1-3'UTR plasmid containing a mutation within the miR-627 recognition site (ACTC to TGAG mutation within 3'UTR) was created by PCR using the QuickChange II site-directed mutagenesis kit (Stratagene), following the supplied protocol. For the miR-627 sponge experiments, the 3'UTR cDNA was also inserted into pRNAT-CMV3.2/Puro plasmid (BamH I and Xho I) to create pRNAT-CMV3.2/Puro-3'UTR for stable transfection into HCT-116 cells. The pRNAT-CMV3.2/Puro-3'UTR-mut containing mutation within the miR-627 recognition site (ATTC to TGAG) in the 3'UTR was created by PCR using the QuickChange II site-directed mutagenesis kit (Stratagene). To construct miRNA expression vectors, double strand oligoes containing pre-miR-627 were cloned into pcDNA6.2-GW/EmGFP-miR plasmid (Invitrogen) by directional cloning. Negative control and CYP3A4 siRNAs were purchased from Ambion. Synthetic miRNA mimics (Pre-miR™ miRNA Precursors) for miRNA-627 (# AM17100) and negative control miR-NC (# AM17110) were purchased from Ambion.
Materials and Methods

Cells and
LC/MS detection for irinotecan and its metabolites: LC/MS was performed as described previously (30) . Chromatography grade acetonitrile (ACN), methanol, and water were purchased from EMD chemicals. Acetic acid (HOAc) was purchased from Sigma. 100 µL culture medium from the cells treated by irinotecan for 48 h was collected, and then mixed with 100 µL ACN and methanol (v/v 1:1) spiked with internal standard, e.g., camptothecin (31) . The mixture was vortexed and set on ice for 5 minutes, and then centrifuged at 13,000 rpm for 10 minute. After centrifugation, supernatant was filtered by syringe filter and transferred to micro-inserts for LC/MS analysis. The LC/MS system consisted of an Agilent 1200 series HPLC system and an Agilent 6300 LC/MSD SL ion trap mass system. Chromatography separations were Correlation significance was assessed using Pearson's correlation coefficient test. P 0.05 was considered to be statistically significant.
Results
Calcitriol-regulated miR-627 Targets CYP3A4
We have recently identified miR-627 as the only microRNA whose expression level was significantly increased by calcitriol in colon cancer cells (18) . Using the computational methods available at www.microrna.org and miRBase (http://microrna.sanger.ac.uk/), we identified CYP3A4 gene as a potential target for miR-627. A recently published computational analysis also agreed with our assessment that miR-627 may target CYP3A4 (32) . CYP3A4 is one of the most important drug-metabolizing enzymes (5), responsible for the first-pass metabolism, elimination time, and levels of drug exposure of many drugs including anti-cancer agents. The CYP3A4 mRNA contains a 3'UTR sequence that is partially complementary to miR-627 ( 
Calcitriol and miR-627 Inhibit Intratumoral CYP3A4-mediated Irinotecan
Metabolism and Enhance the in vitro Antitumor Activity of Irinotecan
Irinotecan is metabolized by CYP3A4 into the inactive metabolites NPC and APC (12) .
Since calcitriol decreases CYP3A4 protein, we examined the effects of calcitriol on irinotecan metabolism within the colon cancer cells. As shown in Figure 2A , calcitriol inhibited CYP3A4-mediated metabolism of irinotecan in HT-29 cells. The levels of metabolic products of irinotecan (NPA and APC) were decreased after calcitriol treatment and the levels of irinotecan were increased. Calcitriol also inhibited irinotecan metabolism by CYP3A4 in HCT-116 cells ( Figure 2B ). While it has been shown that irinotecan induces CYP3A4 expression through steroid and xenobiotic receptor signaling (13), we found that CYP3A4 was suppressed by calcitriol and irinotecan combination treatment (Supplemental Figure 2) . Similarly, overexpression of exogenous miR-627 also decreased the levels of NPC and APC ( Figure 2C ), while the levels of irinotecan were increased. We hypothesized that by inhibiting CYP3A4-mediated inactivation of irinotecan, calcitriol should increase the therapeutic efficacy of irinotecan.
To test this, we treated HT-29 cells first with calcitriol for 24 hours, followed by treatment with various doses of irinotecan. As shown in Figure 3A enhanced the activity of irinotecan in suppression of colon cancer cell proliferation. In addition, pretreatment of calcitriol also increased irinotecan-induced apoptosis ( Figure   3B ). We also observed similar results in HCT-116 cell. Pretreatment with calcitriol increased the activity of irinotecan in growth suppression and induction of apoptosis ( Figure 3C and 3D) . Using the CalcuSyn software, we found that the combination of calcitriol and irinotecan was synergistic (combination index < 1) at all doses in HCT-116 and HT-29 cells (Supplemental Figure 3) .
miR-627 is Necessary and Sufficient to Enhance the Antitumor Activity of Irinotecan
To further determine the role of miR-627 in calcitriol's enhancement of irinotecan's antitumor activity, we overexpressed a cDNA fragment containing a miR-627 target sequence (part of the 3'UTR of JMJD1A gene (18)) in HCT-116 cells. The overexpressed mRNA containing the miR-627 target sequence (driven by a strong CMV promoter) would serve as a "sponge" to sequester and block the activity of miR-627. We employed this miRNA sponge strategy (33, 34) to create HCT-116 cell lines stably expressing the 3'UTR-derived miR-627 sponge for in vitro and in vivo studies. When miR-627 was blocked by the sponge, calcitriol failed to suppress the expression of CYP3A4 ( Figure 4A ). As a result, calcitriol was no longer able to enhance the activity of irinotecan in suppression of cancer cell proliferation ( Figure 4B ), indicating that induction of miR-627 is critical to the action of calcitriol in promoting irinotecan's activity.
In contrast, when the miR-627 binding site was mutated and the sponge did not block miR-627, calcitriol was still able to decrease CYP3A4 ( Figure 4A ) and enhance the 
antitumor activity of irinotecan ( Figure 4B ). To determine if miR-627 alone is sufficient to increase the antitumor activity of irinotecan, we created HCT-116 cells stably expressing miR-627. As shown in Figure 4C , stable expression of miR-627 was able to decrease the expression of CYP3A4. Furthermore, miR-627 expression increased the effects of irinotecan in suppressing cancer cell proliferation ( Figure 4D ) and induction of apoptosis ( Figure 4E ). While miR-627 decreased the expression of CYP3A4 to a greater degree than calcitriol did, we did not observe a more pronounced effect on enhancing irinotecan in growth suppression or induction of apoptosis (when compared to the effects of calcitriol). Overexpression of miR-627 may target other mRNAs that can potentially interfere with the effect on irinotecan.
CYP3A4 is a Critical Target in Calcitriol's Enhancement of the Antitumor Activity of Irinotecan
To further determine the role of CYP3A4 in the antitumor activity of irinotecan, we specifically knocked down CYP3A4 using siRNA. As shown in Figure 5A and 5B, siRNA knockdown of CYP3A4 significantly increased the efficacy of irinotecan in suppressing the proliferation of HT-29 cells (which express relatively higher level of CYP3A4 than HCT-116 cells, data not shown). The effects of CYP3A4 siRNA knockdown on irinotecan were validated using another siRNA targeting different site of the CYP3A4 mRNA (Supplemental Figure 4) . We have previously shown that miR-627-mediated downregulation of JMJD1A is involved in the antitumor activity of calcitriol (18) . To eliminate the possibility that calcitriol may enhance the activity of irinotecan through JMJD1A, we isolated CD133 negative cells from HCT-116. It was shown previously that Figure 7) .
Calcitriol Enhances the in vivo Antitumor Activity of Irinotecan through Induction of miR-627
We have previously demonstrated that calcitriol induces miR-627 expression in vivo in a nude mouse xenograft model (18) . To determine if calcitriol decreases CYP3A4 (through miR-627) expression in vivo, we established human colon cancer xenografts in nude mice and treated the mice with calcitriol. As shown in Figure 6A without inducing any toxicity (measured by the loss of body weight), as shown in Figures 6B. We did not observe any symptoms of toxicity in the mice (lethargy, decreased feeding, etc). In contrast, when we blocked the activity of miR-627 using the 3'UTR sponge which can sequester miR-627 and calcitriol was no longer able to decrease CYP3A4 (Figure 4A) , not only did calcitriol fail to suppress xenograft growth, but also it failed to enhance the activity of irinotecan in tumor suppression in the nude mice, Figure 6C 
Discussion
Drug resistance is a major problem in cancer chemotherapy (38) . Multiple mechanisms have been intensively studied to understand the causes of drug resistance. While most of previous studies have focused on multidrug resistance genes (such as P-glycoprotein) (39), anti-apoptotic genes (40) , and overexpression/amplification of drug targets (41, 42) , few attention was given to drug metabolism as a mechanism for drug resistance. Studies to identify a solution to metabolism-mediated drug resistance were even rare. In this study, we have demonstrated that CYP3A4-mediated metabolism of irinotecan can potentially serve as a mechanism of drug resistance. More importantly, miR-627-mediated downregulation of CYP3A4 can provide a mechanism to overcome such resistance to irinotecan. By activating miR-627, calcitriol can be employed to enhance the anticancer activity of irinotecan, a major therapeutic agent for colon cancer. Thus, our findings provide an effective solution to the intratumoral inactivation of irinotecan by CYP3A4, i.e., using the widely available vitamin D to downregulate CYP3A4 and improve the efficacy of irinotecan.
CYP3A4 is a major drug metabolism enzyme expressed in the liver (43) .
Interestingly, previous studies have demonstrated that vitamin D induces CYP3A4
expression in the liver (44) . This opposite effect of vitamin D on CYP3A4 in the liver can be utilized to the benefit of reducing the systemic toxicities of irinotecan. In fact, irinotecan has three main dose-limiting toxicities: myelosuppression, diarrhea, and neutropenia. About 70% of patients receiving irinotecan treatment suffer from diarrhea, which makes an increased dosing schedule difficult (45) . Approximately 55% of these 
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repeated three times; representative results of three independent experiments were shown. Data shown are mean values + SD (*p<0.05, **p<0.01, ***p<0.001). Treatments were given on the underlined dates. Tumor volumes and body weights were measured at the indicated time points. The data of the irinotecan and calcitriol/irinotecan combination groups were plotted with a different scale using the Right Axis, (*p<0.05, **p<0.01). 
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